Fuji Pharma Co., Ltd.

Tokyo Stock Exchange 4554.T

Fuji Pharma Co., Ltd. Receivables for the year ending September 30, 2024: USD 0.00

Fuji Pharma Co., Ltd. Receivables is USD 0.00 for the year ending September 30, 2024, a -100.00% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Fuji Pharma Co., Ltd. Receivables for the year ending September 30, 2023 was USD 109.11 M, a 26.10% change year over year.
Fuji Pharma Co., Ltd. Receivables for the year ending September 30, 2022 was USD 86.52 M, a -18.84% change year over year.
Fuji Pharma Co., Ltd. Receivables for the year ending September 30, 2021 was USD 106.60 M, a -3.92% change year over year.
Fuji Pharma Co., Ltd. Receivables for the year ending September 30, 2020 was USD 110.95 M, a -7.33% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Tokyo Stock Exchange: 4554.T

Fuji Pharma Co., Ltd.

CEO	Mr. Toyoyuki Kamide
IPO Date	Feb. 22, 2010
Location	Japan
Headquarters	5-7 Sanban-cho
Employees	1,621
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Cosmetics Drugstores & Retail Pharmacies Medical Instruments Personal Care

Description

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years